Cargando…
Rivaroxaban for cancer-associated venous thromboembolism: A systematic review and meta-analysis protocol
BACKGROUND: All cancers increase developing venous thromboembolism risk, and VTE is the second-leading cause of death among cancer patients. The anticoagulant drugs are considered to be the optimal treatment for patients with cancer-associated VTE. However, there is still controversy whether rivarox...
Autores principales: | Liang, Bo, Zhao, Li-Zhi, Liao, Hui-Ling, Gu, Ning |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890290/ https://www.ncbi.nlm.nih.gov/pubmed/31770226 http://dx.doi.org/10.1097/MD.0000000000018087 |
Ejemplares similares
-
Rivaroxaban for cancer-associated venous thromboembolism
por: Liang, Bo, et al.
Publicado: (2021) -
Incidence of venous thromboembolism following the neoadjuvant chemotherapy regimen for epithelial type of ovarian cancer
por: Chavan, Devendra Manik, et al.
Publicado: (2017) -
Interventions for cancer-related pain: Protocol of an umbrella systematic review and network meta-analysis
por: Xu, Tao, et al.
Publicado: (2019) -
A comprehensive evaluation of single nucleotide polymorphisms associated with osteosarcoma risk: A protocol for systematic review and network meta-analysis
por: Ye, Zhuo-Miao, et al.
Publicado: (2020) -
Relationship between ABO blood group and risk of venous thrombosis in cancer patients with peripherally inserted central catheters: A protocol for systematic review and meta-analysis
por: Liu, Fangjing, et al.
Publicado: (2020)